In the last 30 years, rapid, accelerated knowledge gain due to an increasing number of publications on pathobiology and clinical trials have led to more tailored (“personalized”), goal oriented treatment modalities for PAH. New insights into metabolic dysregulation and previously unknown gene mutations, and high impact, high volume, longterm randomized controlled trials (RCT) using combined outcomes such as “first morbidity and mortality”, have been published, leading to the approval of more PAH drugs acting on previously known pathways. However, prospective studies in children and adolescents with PAH are largely lacking.
The number of publications addressing experimental therapies in PAH began to increase in 1995 after landmark studies in human PAH tissues and randomized controlled clinical PAH trials had been published.
To evaluate the number of publications addressing experimental therapies in pulmonary arterial hypertension (PAH), the search engine Web of Science, which is a citation database of research literature, was used (www.webofknowledge.com). In the advanced search options we refined our outline query to Pulmonary Arterial Hypertension AND therapies and analyzed the Number of publications within the years 1990 and 2019.